The effects of combining angiotensin-receptor blockers of different peroxisome proliferator-activated receptor γ-activating capacity with rosuvastatin on high-density lipoprotein (HDL) subfractions and associated enzymes in patients with mixed dyslipidemia, hypertension, and prediabetes were assessed. Patients (n = 151) were randomly allocated to rosuvastatin (10 mg/d) plus telmisartan 80 mg/d (RT group, n = 52) or irbesartan 300 mg/d (RI group, n = 48) or olmesartan 20 mg/d (RO group, n = 51). Total and intermediate HDL cholesterol (HDL-C) levels did not change in any group. Large HDL-C increased, while small HDL-C decreased significantly in all the groups (P = not significant between the groups). The mass of HDL lipoprotein-associated phospholipase A2 (HDL-Lp-PLA2) and the activities of paraoxonase 1 remained unchanged in all the groups. However, HDL-Lp-PLA2 activity increased only in the RT group (+21.4%; P < .01 vs baseline) and did not change in the RI (−4.3%; P = .005 vs RT group) and RO (+3.2%; P = .01 vs RT) groups. In conclusion, only the combination of rosuvastatin with telmisartan increased the possibly antiatherosclerotic HDL-Lp-PLA2 activity.
AsztalosBFCupplesLADemissieS. High-density lipoprotein subpopulation profile and coronary heart disease prevalence in male participants of the Framingham Offspring Study. Arterioscler Thromb Vasc Biol. 2004;24(11):2181–2187.
4.
TellisCCTselepisAD. The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma. Biochim Biophys Acta. 2009;1791(5):327–338.
5.
KarabinaSALiapikosTAGrekasGGoudevenosJTselepisAD. Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions. Biochim Biophys Acta. 1994;1213(1):34–38.
6.
RallidisLSTellisCCLekakisJ. Lipoprotein-associated phospholipase A(2) bound on high-density lipoprotein is associated with lower risk for cardiac death in stable coronary artery disease patients: a 3-year follow-up. J Am Coll Cardiol. 2012;60(20):2053–2060.
7.
MacknessMIDurringtonPN. HDL, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 1995;115(2):243–253.
8.
MacknessMIDurringtonPNMacknessB. The role of paraoxonase 1 activity in cardiovascular disease: potential for therapeutic intervention. Am J Cardiovasc Drugs. 2004;4(4):211–217.
9.
BensonSCPershadsinghHAHoCI. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension. 2004;43(5):993–1002.
10.
RizosCVMilionisHJKostapanosMS. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study. Clin Ther. 2010;32(3):492–505.
11.
RizosCVLiberopoulosENTellisCCTselepisADElisafMS. The effect of combining rosuvastatin with sartans of different peroxisome proliferator receptor-gamma activating capacity on plasma 8-isoprostane prostaglandin F2a levels. Arch Med Sci. 2013;9(1):172–176.
12.
RizosCVElisafMSKeiALiberopoulosEN. The effects of combining rosuvastatin with sartans of different PPARγ activating capacity on liver function tests in overweight/obese subjects with hypertension, mixed hyperlipidemia and impaired fasting glucose. Cardiovasc Continuum. 2011;2:24–29.
13.
RizosCVLiberopoulosENElisafMS. The renal effects of combining rosuvastatin with angiotensin receptor blockers of different PPARγ activating capacity. Hellenic J Atheroscleros. 2011;2(3):215–222.
14.
RizosCVLiberopoulosENTellisCCFlorentinMElisafMSTselepisAD. Combining rosuvastatin with sartans of different peroxisome proliferator-activated receptor-gamma activating capacity is not associated with different changes in low-density lipoprotein subfractions and plasma lipoprotein-associated phospholipase A(2). Metab Syndr Relat Disord. 2011;9(3):217–223.
15.
SacksFMSvetkeyLPVollmerWM. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. DASH-sodium collaborative research group. N Engl J Med. 2001;344(1):3–10.
16.
KostapanosMSMilionisHJFilippatosTD. Dose-dependent effect of rosuvastatin treatment on HDL-subfraction phenotype in patients with primary hyperlipidemia. J Cardiovasc Pharmacol Ther. 2009;14(1):5–13.
17.
TselepisADDentanCKarabinaSAChapmanMJNinioE. PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme. Arterioscler Thromb Vasc Biol. 1995;15(10):1764–1773.
18.
LiberopoulosENPapavasiliouEMiltiadousGA. Alterations of paraoxonase and platelet-activating factor acetylhydrolase activities in patients on peritoneal dialysis. Perit Dial Int. 2004;24(6):580–589.
19.
KontushAChapmanMJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall?Nat Clin Pract Cardiovasc Med. 2006;3(3):144–153.
20.
TselepisADJohn ChapmanM. Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase. Atheroscler Suppl. 2002;3(4):57–68.
21.
AsztalosBFCollinsDCupplesLA. Value of high-density lipoprotein (HDL) subpopulations in predicting recurrent cardiovascular events in the Veterans Affairs HDL Intervention Trial. Arterioscler Thromb Vasc Biol. 2005;25(10):2185–2191.
22.
Otocka-KmiecikAMikhailidisDPNichollsSJDavidsonMRyszJBanachM. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?Prog Lipid Res. 2012;51(4):314–324.
23.
SaougosVGTambakiAPKalogirouM. Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol. 2007;27(10):2236–2243.
24.
RizosECSpyrouALiberopoulosEN. Effects of eprosartan on serum metabolic parameters in patients with essential hypertension. Open Cardiovasc Med J. 2007;1:22–26.
25.
RizosCVElisafMSLiberopoulosEN. Are the pleiotropic effects of telmisartan clinically relevant?Curr Pharm Des. 2009;15(24):2815–2832.
26.
AkiyamaTESakaiSLambertG. Conditional disruption of the peroxisome proliferator-activated receptor gamma gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol. 2002;22(8):2607–2619.
27.
MalerodLSporstolMJuvetLKMousaviAGjoenTBergT. Hepatic scavenger receptor class B, type I is stimulated by peroxisome proliferator-activated receptor gamma and hepatocyte nuclear factor 4alpha. Biochem Biophys Res Commun. 2003;305(3):557–565.
28.
RizosCVLiberopoulosENMikhailidisDPElisafMS. Pleiotropic effects of thiazolidinediones. Expert Opin Pharmacother. 2008;9(7):1087–1108.
29.
LawrenceJMReidJTaylorGJStirlingCRecklessJP. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Diabetes Care. 2004;27(1):41–46.
30.
FilippatosTDRizosECTsimihodimosVGaziIFTselepisADElisafMS. Small high-density lipoprotein (HDL) subclasses are increased with decreased activity of HDL-associated phospholipase A(2) in subjects with prediabetes. Lipids. 2013;48(6):547–555.
31.
TambakiAPRizosETsimihodimosVTselepisADElisafM. Effects of antihypertensive and hypolipidemic drugs on plasma and high-density lipoprotein-associated platelet activating factor-acetylhydrolase activity. J Cardiovasc Pharmacol Ther. 2004;9(2):91–95.
32.
RizosETambakiAPGaziITselepisADElisafM. Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome. Prostaglandins Leukot Essent Fatty Acids. 2005;72(3):203–209.
33.
ParsaeyanNMozaffari-KhosraviHMozayanMR. Effect of pomegranate juice on paraoxonase enzyme activity in patients with type 2 diabetes. J Diabetes Metab Disord. 2012;11(1):11.
34.
KouchakADjalaliMEshraghianMSaedisomeoliaADjazayeryAHajianfarH. The effect of Omega-3 fatty acids on serum paraoxonase activity, vitamins A, E, and C in type 2 diabetic patients. J Res Med Sci. 2011;16(7):878–884.
